Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial
Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial. // JHEP Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2589555926003095?dgcid=rss_sd_all
Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial. JHEP Reports. https://www.sciencedirect.com/science/article/pii/S2589555926003095?dgcid=rss_sd_all
“Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial.” JHEP Reports.
@article{article51112,
title = {Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial},
journal = {JHEP Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2589555926003095?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...